These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 35898799)
21. Molnupiravir, an Oral Antiviral Treatment for COVID-19. Fischer W; Eron JJ; Holman W; Cohen MS; Fang L; Szewczyk LJ; Sheahan TP; Baric R; Mollan KR; Wolfe CR; Duke ER; Azizad MM; Borroto-Esoda K; Wohl DA; Loftis AJ; Alabanza P; Lipansky F; Painter WP medRxiv; 2021 Jun; ():. PubMed ID: 34159342 [TBL] [Abstract][Full Text] [Related]
22. Development and validation of assays for the quantification of β-D-N Parsons TL; Kryszak LA; Marzinke MA J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Oct; 1182():122921. PubMed ID: 34555541 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of the mutagenic effects of Molnupiravir and N4-hydroxycytidine in bacterial and mammalian cells by HiFi sequencing. Miranda JA; McKinzie PB; Dobrovolsky VN; Revollo JR Environ Mol Mutagen; 2022 Aug; 63(7):320-328. PubMed ID: 36181379 [TBL] [Abstract][Full Text] [Related]
24. Synthesis and Antiviral Activity of Novel β-D-N4-Hydroxycytidine Ester Prodrugs as Potential Compounds for the Treatment of SARS-CoV-2 and Other Human Coronaviruses. Darnotuk ES; Siniavin AE; Shastina NS; Luyksaar SI; Inshakova AM; Bondareva NE; Zolotov SA; Lubenec NL; Sheremet AB; Logunov DY; Zigangirova NA; Gushchin VA; Gintsburg AL Pharmaceuticals (Basel); 2023 Dec; 17(1):. PubMed ID: 38256869 [TBL] [Abstract][Full Text] [Related]
25. Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial. Zou R; Peng L; Shu D; Zhao L; Lan J; Tan G; Peng J; Yang X; Liu M; Zhang C; Yuan J; Wang H; Li S; Lu H; Zhong W; Liu Y Front Pharmacol; 2022; 13():939573. PubMed ID: 35784723 [No Abstract] [Full Text] [Related]
26. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. Gordon CJ; Tchesnokov EP; Schinazi RF; Götte M J Biol Chem; 2021 Jul; 297(1):100770. PubMed ID: 33989635 [TBL] [Abstract][Full Text] [Related]
27. Uridine-cytidine kinase 2 potentiates the mutagenic influence of the antiviral β-d-N4-hydroxycytidine. Xu Z; Flensburg C; Bilardi RA; Majewski IJ Nucleic Acids Res; 2023 Dec; 51(22):12031-12042. PubMed ID: 37953355 [TBL] [Abstract][Full Text] [Related]
28. Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity. Hadj Hassine I; Ben M'hadheb M; Menéndez-Arias L Viruses; 2022 Apr; 14(4):. PubMed ID: 35458571 [TBL] [Abstract][Full Text] [Related]
29. Real-Life Experience of Molnupiravir in Hospitalized Patients Who Developed SARS-CoV2-Infection: Preliminary Results from CORACLE Registry. Lupia T; Corcione S; Shbaklo N; Boglione L; Torresan S; Pinna SM; Rizzello B; Bosio R; Fornari V; Brusa MT; Borrè S; De Rosa FG Antibiotics (Basel); 2022 Nov; 11(11):. PubMed ID: 36358196 [TBL] [Abstract][Full Text] [Related]
30. Synthesis of Novel Amblard F; LeCher JC; De R; Goh SL; Li C; Kasthuri M; Biteau N; Zhou L; Tber Z; Downs-Bowen J; Zandi K; Schinazi RF Pharmaceuticals (Basel); 2022 Sep; 15(9):. PubMed ID: 36145365 [TBL] [Abstract][Full Text] [Related]
31. Effectiveness of Antiviral Therapy in Highly-Transmissible Variants of SARS-CoV-2: A Modeling and Simulation Study. Schöning V; Kern C; Chaccour C; Hammann F Front Pharmacol; 2022; 13():816429. PubMed ID: 35222030 [TBL] [Abstract][Full Text] [Related]
32. The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review. Kamal L; Ramadan A; Farraj S; Bahig L; Ezzat S Saudi Pharm J; 2022 May; 30(5):508-518. PubMed ID: 35287313 [TBL] [Abstract][Full Text] [Related]
33. Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 Treatment. Githaka JM Bioinform Biol Insights; 2022; 16():11779322221085077. PubMed ID: 35342288 [TBL] [Abstract][Full Text] [Related]
34. Sustainable Stability-Indicating spectra manipulations for the concurrent quantification of a novel Anti-COVID-19 drug and its active Metabolite: Green profile assessment. Gamal Fawzy M; Kamel EB Spectrochim Acta A Mol Biomol Spectrosc; 2023 Nov; 300():122911. PubMed ID: 37267836 [TBL] [Abstract][Full Text] [Related]
35. Characterization of the First SARS-CoV-2 Isolates from Aotearoa New Zealand as Part of a Rapid Response to the COVID-19 Pandemic. Harfoot R; Lawley B; Hernández LC; Kuang J; Grant J; Treece JM; LeQueux S; Day R; Jack S; Stanton JL; Bostina M; Ussher JE; Quiñones-Mateu ME Viruses; 2022 Feb; 14(2):. PubMed ID: 35215963 [TBL] [Abstract][Full Text] [Related]
36. Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2. Holman W; Holman W; McIntosh S; Painter W; Painter G; Bush J; Cohen O Trials; 2021 Aug; 22(1):561. PubMed ID: 34425873 [TBL] [Abstract][Full Text] [Related]
37. Molnupiravir, favipiravir and other antiviral drugs with proposed potentials for management of COVID-19: a concern on antioxidant aspect. Yasri S; Wiwanitki V Int J Biochem Mol Biol; 2022; 13(1):1-4. PubMed ID: 35295914 [TBL] [Abstract][Full Text] [Related]
38. Molnupiravir as an Early Treatment for COVID-19: A Real Life Study. Pontolillo M; Ucciferri C; Borrelli P; Di Nicola M; Vecchiet J; Falasca K Pathogens; 2022 Sep; 11(10):. PubMed ID: 36297178 [TBL] [Abstract][Full Text] [Related]
39. Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo. Li Y; Liu M; Yan Y; Wang Z; Dai Q; Yang X; Guo X; Li W; Chen X; Cao R; Zhong W Viruses; 2022 May; 14(6):. PubMed ID: 35746614 [TBL] [Abstract][Full Text] [Related]